Galectin Therapeutics Inc.
GALT
$3.31
-$0.22-6.23%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.18M | -7.52M | -9.63M | -11.97M | -11.22M |
| Total Depreciation and Amortization | 0.00 | 2.00K | 10.00K | 10.00K | 9.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.92M | 1.95M | 840.00K | -1.16M | 1.56M |
| Change in Net Operating Assets | 1.73M | -1.03M | 1.09M | 326.00K | 1.11M |
| Cash from Operations | -3.54M | -6.60M | -7.69M | -12.79M | -8.54M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 0.00 | 11.00M | -- | 0.00 | 10.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.30M | 1.94M | -- | 851.00K | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.30M | 12.94M | -- | 851.00K | 10.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.25M | 6.34M | -7.69M | -11.94M | 1.46M |